{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:57:57Z","timestamp":1768687077097,"version":"3.49.0"},"reference-count":65,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J of Neuroscience"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ability of CGP 3466B to attenuate the behavioural and morphological consequences of experimentally induced cell death was investigated in a recently updated animal model of Parkinson's disease. 6\u2010Hydroxydopamine was infused bilaterally into the substantia nigra pars compacta of rats that were pretreated with desimipramine. Treatment with CGP 3466B (0.0014\u20131.4\u2003mg\/kg, injected subcutaneously) or its solvent was begun 2\u2003h after the 6\u2010OHDA injection, and maintained twice daily for 14\u2003days. After a washout period of 14\u2003days, changes in motor behaviour were evaluated, using the open field test (analysis of normal and abnormal stepping, e.g.) and the paw test (analysis of retraction time of limbs). Changes in learning and memory were evaluated with the help of the Morris water maze task. Following immunocytochemical staining of tyrosine hydroxylase, the extent of the lesion was quantified using a computerized system. CGP 3466B prevented all deficits produced by 6\u2010hydroxydopamine (6\u2010OHDA), though at different doses. It prevented: abnormal stepping (0.0014\u20130.014\u2003mg\/kg); increased forelimb and hindlimb retraction time (0.014\u20130.14\u2003mg\/kg and 0.0014\u20130.14\u2003mg\/kg, respectively); delayed learning (1.4\u2003mg\/kg); and reduced tyrosine hydroxylase immunoreactivity in the substantia nigra (0.0014\u20130.014\u2003mg\/kg). CGP 3466B (0.0014\u20130.14\u2003mg\/kg) induced no deficits in sham\u2010treated rats. CGP 3466B (1.4\u2003mg\/kg), however, did not show any benefit on motor deficits in 6\u2010OHDA\u2010lesioned rats, and induced abnormal movements and decreased the tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and the ventral tegmental area of sham\u2010lesioned animals. It is concluded that CGP 3466B prevents all 6\u2010OHDA\u2010induced behavioural and immunocytochemical deficits, though at different doses. CGP 3466B is suggested to be a valuable agent for inhibiting the dopaminergic degeneration in patients with Parkinson's disease.<\/jats:p>","DOI":"10.1046\/j.1460-9568.2000.00181.x","type":"journal-article","created":{"date-parts":[[2003,3,6]],"date-time":"2003-03-06T14:33:29Z","timestamp":1046961209000},"page":"3033-3043","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6\u2010hydroxydopamine\u2010induced lesions in the substantia nigra"],"prefix":"10.1111","volume":"12","author":[{"given":"G.","family":"Andringa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. V.","family":"Van Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. G. M.","family":"Hafmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Veening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Stoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Cools","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"25","article-title":"Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease","volume":"12","author":"Anglade P.","year":"1997","journal-title":"Histol. Histopathol."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00896.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(95)00112-v"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1971.tb07089.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7020.1583"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/nlme.1997.3793"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(80)90035-2"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(90)90288-B"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(91)90256-J"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90551-6"},{"key":"e_1_2_6_12_1","first-page":"495","article-title":"Pharmacology of rasagiline (N\u2010propargyl\u20101R\u2010aminoindan)","volume":"80","author":"Finberg J.P.","year":"1999","journal-title":"Adv. Neurol."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890130209"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-3057(98)00162-2"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1996.66052004.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(99)02459-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(80)90871-9"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00505805"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-1119(99)00443-6"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_3.161S"},{"key":"e_1_2_6_21_1","first-page":"554","article-title":"CGP 3466B, a dibenzoxepine derivate, increases life\u2010span in an animal model of motoneuron disease","volume":"23","author":"Kato A.C.","year":"1997","journal-title":"Soc. Neurosci. Abstract."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6848"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00184-7"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.10.5821"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb05025.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9861(19971124)388:3<484::aid-cne10>3.0.co;2-m"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733020-00002"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0047-6374(99)00066-4"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(84)90007-4"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-23-07768.1996"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1985.tb10556.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68010033.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68010434.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_3.210S"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995"},{"issue":"1","key":"e_1_2_6_36_1","article-title":"CGP3466 prevents neuronal death in models of ischaemia and seizure in vivo","volume":"70","author":"Paterson I.A.","year":"1998","journal-title":"J. Neurochem."},{"issue":"1","key":"e_1_2_6_37_1","article-title":"CGP 3466 and CGP 3466B prevent cytosine arabinoside\u2010induced apoptosis in cultures of cerebellar neurones","volume":"70","author":"Paterson I.A.","year":"1998","journal-title":"J. Neurochem."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70020515.x"},{"key":"e_1_2_6_39_1","volume-title":"The Rat Brain in Stereotaxic Coordinates.","author":"Paxinos G.","year":"1982"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91533-4"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6\u2010hydroxydopamine: a combined retrograde tracing and immunocyto\u2010chemical study in the rat","volume":"59","author":"Sauer H.","year":"1994","journal-title":"Neuroscience"},{"key":"e_1_2_6_42_1","first-page":"689","article-title":"Behavioural and neurochemical dynamics of neurotoxic meso\u2010striatal dopamine lesions","volume":"18","author":"Schwarting R.K.","year":"1997","journal-title":"Neurotoxicology"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000116869"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(99)00119-3"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(73)90001-2"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/18.5.315"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12098-o"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1857-0_2"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_3.171S"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490300410"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.63041572.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012525445-8\/50014-X"},{"key":"e_1_2_6_53_1","first-page":"119","article-title":"Apoptotic\u2010like changes in Lewy\u2010body\u2010associated disorders and normal aging in substantia nigral neurons","volume":"150","author":"Tompkins M.M.","year":"1997","journal-title":"Am. J. Pathol."},{"key":"e_1_2_6_54_1","first-page":"220","article-title":"Adipsia and aphagia after 6\u2010hydroxydopamine induced degeneration of the nigro\u2010striatal dopamine system. Acta Physiol","volume":"367","author":"Ungerstedt U.","year":"1971","journal-title":"Scand. Suppl."},{"key":"e_1_2_6_55_1","first-page":"421","article-title":"Behavioural, physiological, and neurochemical changes after 6\u2010hydroxydopamine\u2010induced degeneration of the nigro\u2010striatal dopamine neurons","volume":"5","author":"Ungerstedt U.","year":"1974","journal-title":"Adv. Neurol."},{"key":"e_1_2_6_56_1","first-page":"1644","article-title":"A subtle unilateral 6\u2010OHDA lesion, specific of the A9 cell\u2010group, changes the A9 and A10 function in behavioural programs of two types of Wistar rat","volume":"645","author":"Van Oosten R.V.","year":"1998","journal-title":"Soc. Neurosci. Abstract."},{"key":"e_1_2_6_57_1","article-title":"Neurorescuing effects of the GAPDH ligand CGP 3466B","author":"Waldmeier P.C.","year":"2000","journal-title":"J. Neural Transm."},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90566-5"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(85)90186-6"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-4328(96)00148-9"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(85)90165-2"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb11786.x"},{"key":"e_1_2_6_63_1","first-page":"S45","article-title":"Neuroprotective properties of the antiparkinson drug rasagiline and its optical S\u2010isomer. Neurosci","volume":"54","author":"Youdim M.B.H.","year":"1999","journal-title":"Lett. Suppl."},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)61208-X"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04050190062015"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(08)60277-9"}],"container-title":["European Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1460-9568.2000.00181.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1460-9568.2000.00181.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T07:38:03Z","timestamp":1696405083000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1460-9568.2000.00181.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1046\/j.1460-9568.2000.00181.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1460-9568.2000.00181.x","archive":["Portico"],"relation":{},"ISSN":["0953-816X","1460-9568"],"issn-type":[{"value":"0953-816X","type":"print"},{"value":"1460-9568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}